Related Experiment Videos
Dynamics of suppressor T cells: in vivo veritas
1Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney St., Smith 736, Boston, MA 02115, USA. harald_von_boehmer@dfci.harvard.edu
The Journal of Experimental Medicine
|September 17, 2003
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes".
The Journal of experimental medicine·2017
Cyclin C is a haploinsufficient tumour suppressor.
Nature cell biology·2014
The thymus in immunity and in malignancy.
Cancer immunology research·2014
Negative selection, not receptor editing, is a physiological response of autoreactive thymocytes.
The Journal of experimental medicine·2013
The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
The Journal of experimental medicine·2013
The transcriptional landscape of αβ T cell differentiation.
Nature immunology·2013
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.
The Journal of experimental medicine·2026
Human-inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity.
The Journal of experimental medicine·2026
Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine.
The Journal of experimental medicine·2026
Functional heterogeneity and plasticity in naïve CD8 T cells drive superior effector and memory responses.
The Journal of experimental medicine·2026
PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization.
The Journal of experimental medicine·2026
Borrelia burgdorferi disrupts gut barrier functions and microbiota-antibody interactions.
The Journal of experimental medicine·2026
Role of T Cells in Chronic Pain: Mechanisms, Regulation, and Therapeutic Implications.
Immunology and cell biology·2026
Targeting the myeloid immune checkpoint ILT3 (LILRB4) with small molecules enables reprogramming of suppressive tumor immunity.
European journal of medicinal chemistry·2026
From spatial maps to treatment decisions: a roadmap for integrating explainable AI with multi-omics to guide precision immunotherapy.
Biotechnology notes (Amsterdam, Netherlands)·2026